Clinical trial
A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
NCT00083889 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized Study Of SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma
- Lead sponsor
- Pfizer
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- August 31, 2004
- Completion date
- September 30, 2008
- Enrollment
- 750 (actual)
- Sites
- 123
Conditions
As the registry lists them; a condition with its own page is linked.